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BACKGROUND: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also
has activity against CaP. Of importance to metastatic CaP, which frequently metastasises to bone, SFK are also vital to the regulation
of bone remodelling. We sought to determine the ability of dasatinib to inhibit growth of CaP in bone.
METHODS: C4-2B CaP cells were injected into tibiae of SCID mice and treated with dasatinib, alone or in combination with docetaxel.
Serum prostate-specific antigen levels, bone mineral density, radiographs and histology were analysed.
RESULTS: Treatment with dasatinib alone significantly lowered sacrifice serum prostate-specific antigen levels compared to control,
2.3±0.4 vs 9.2±2.1 (P¼0.004). Combination therapy improved efficacy over dasatinib alone (P¼0.010). Dasatinib increased bone
mineral density in tumoured tibiae by 25% over control tumoured tibiae (Po0.001).
CONCLUSION: Dasatinib inhibits growth of C4-2B cells in bone with improved efficacy when combined with docetaxel. Additionally,
dasatinib inhibits osteolysis associated with CaP. These data support further study of dasatinib in clinical trials for men with CaP bone
metastases.
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The need for therapies offering improved efficacy in the treatment
of metastatic prostate cancer (CaP) has sparked an area of intense
research. Although current docetaxel-based regimens offer in-
creased survival over previous standard therapies for men with
castration-resistant metastatic CaP, this only results in an
improvement in median survival of 2–3 months, with a median
overall survival of only 18–19 months (Petrylak et al, 2004;
Tannock et al, 2004). Novel therapies with greater efficacy, either
alone or in combination with docetaxel, are needed to further
benefit afflicted men.
The Src family kinases (SFK) represent a nine-member group of
non-receptor tyrosine kinases. Of this family, src is most
extensively characterised. It is involved in cellular proliferation,
survival, motility and angiogenesis (Yeatman, 2004). Src, as well as
lyn, another SFK member, are overexpressed in CaP, and increased
src expression correlates with disease progression (Goldenberg-
Furmanov et al, 2004; Asim et al, 2008).
Src also regulates osteoclast function (Miyazaki et al, 2006).
Src signalling is instrumental in formation of the sealing zone
between the osteoclast and bone matrix, which is necessary for
bone resorption (Destaing et al, 2008). Further support of src
involvement in the regulation of osteoclast activity is demonstrated
by the osteopetrotic phenotype observed in src knockout mice
despite morphologically normal appearing osteoclasts (Soriano
et al, 1991). Additionally, src inhibition was also reported to
increase apoptosis of mature osteoclasts both in vitro and in vivo
(Recchia et al, 2004).
The role of src in bone resorption is particularly relevant to CaP,
which has a proclivity to metastasise to and invade bone (Roudier
et al, 2003). CaP metastases are mainly osteoblastic in character;
however, increased bone destruction is also associated with growth
of CaP cells in the bone environment (Morrissey et al, 2007).
Moreover, current treatment for advanced CaP patients includes
androgen deprivation, which induces loss of bone mineral density
(BMD; Galva ˜o et al, 2008).
Dasatinib is an orally available inhibitor of Bcr-Abl kinase and
SFK proteins and is FDA approved as a second line treatment for
chronic myelogenous leukaemia and Philadelphia chromosome-
positive acute lymphoblastic leukaemia. Recently, dasatinib has
been shown to inhibit proliferation, cell adhesion, migration and
invasion of CaP cells in vitro (Lombardo et al, 2004; Nam et al,
2005). Furthermore, dasatinib decreased the growth of PC-3 CaP
cells injected orthotopically, reduced the number of metastases
and inhibited growth at the metastatic site (Park et al, 2008; Yano
et al, 2008).
CaP is a disease of significant heterogeneity and has historically
been resistant to cytotoxic chemotherapies. Therefore, there is a
substantial need to discover therapies that offer additive or
synergistic properties (McCarty, 2004). Given the in vitro and
preclinical activity of dasatinib, the frequency at which CaP
metastasises to bone, and the role of src in the regulation of
osteoclast function, we sought to determine the ability of dasatinib,
alone and in combination with docetaxel, to inhibit the growth of
CaP in bone and affect bone remodelling. Received 30 March 2009; revised 8 June 2009; accepted 11 June 2009
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Cell line
The C4-2B cell line (a gift from Dr Chung, Emory University) is a
castration-resistant CaP cell line isolated from the bony metastasis
of a mouse xenograft inoculated with C4-2 CaP cells, a subline
of LNCaP CaP cells (Thalmann et al, 1994). C4-2B cells express
androgen receptor, and when growing in the bone they elicit mixed
osteolytic/osteoblastic reaction, which mimics the situation in
human CaP bone metastases (Wu et al, 1998).
In vitro proliferation studies
C4-2B CaP cells were plated at a density of 200000 cells per well in
2ml of RPMI supplemented with 5% FBS. After 24h, dasatinib
(Bristol-Meyers-Squib Inc., Princeton, NJ, USA) was added to the
cells at 12, 37, 111, 333, 1000, 3000 or 9000nM concentrations. After
3 days, cell counts were determined using the trypan blue assay.
Proliferation assays were performed in triplicate and repeated
twice. PSA levels were measured directly from the media of treated
and untreated cells (IMx Total PSA Assay; Abbott Laboratories,
Abbott Park, IL, USA).
Western blot analysis
C4-2B cells were treated with 100nM dasatinib for 0.5, 1, 2, 4, 6 and
24h. Whole cell lysates were prepared as we described previously
(Brubaker et al, 2003). Protein concentrations were determined
with a BCA assay (Bio-Rad Lab., Hercules, CA, USA). Total protein
(20–50mg) were resolved on 4–20% SDS–PAGE and transferred
to PVDF membranes (Bio-Rad). Membranes were blocked for 2h
with 5% BSA in for phospho-Src or with 5% non-fat milk. Rabbit
polyclonal antibody to phospho-[Y
416]-Src Family Kinase (SFK;
1:1000; Cell Signaling Technology, Danvers, MA, USA), to PSA
(2mgml
 1; DAKO, Carpenteria, CA, USA) and to GAPDH (1:2000;
Cell Signaling Technology) were used. Goat anti-rabbit antibodies
conjugated to HRP (1:2000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and ECL (Genscript, Piscataway, NJ, USA) were
used for detection of immunoreactivity.
Immunoprecipitation
C4-2B cells were treated with 100nM dasatinib for 1h. Cells were
harvested, whole cell lysates were prepared, and protein concen-
trations were determined as described above. Dynal Protein A
Dynabeads (50ml; Invitrogen, Carslbad, CA, USA) was mixed with
5mg of a rabbit polyclonal antibody to lyn (05-677; Millipore,
Billerica, MA, USA) or with 5mg of a rabbit polyclonal antibody
to src (ab7950; Abcam, Cambridge, MA, USA) and used for
immunoprecipitation reactions. The primary antibody–bead
complex was blocked and then incubated with 200mg of whole
cell lysate overnight at 41C. Protein complexes were released from
the beads and separated on SDS–PAGE. Western blot was done
using rabbit anti-phospho[Y
416]-SFK antibody (1:1000; Cell
Signaling Technology) to detect phosphorylated lyn and src.
Controls were performed with rabbit polyclonal IgG (1:100).
In vivo studies
All animal procedures were performed in compliance with the
University of Washington Institutional Animal Care and Use
Committee and NIH guidelines. Intratibial injections were carried
out as we described previously (Corey et al, 2002). Briefly, 6-week-
old male SCID mice were injected with B2 10
5 C4-2B cells into
the proximal aspect of the right tibiae. A total of 48 animals were
injected, and 4 weeks after the tumour cell injection animals that
had serum PSA level 40.6ngml
 1 (IMx Total PSA Assay) were
randomised into four groups using the following design: (1) a
control group receiving placebo treatment (n¼8, PSA – 4.376±
1.13ngml
 1 (mean±s.e.m.)); (2) a group receiving docetaxel at
5mgkg
 1 (Morgan et al, 2008; n¼7, PSA – 6.507±1.38ngml
 1);
(3) a group receiving dasatinib only at 50mgkg
 1 (n¼8, PSA –
6.136±0.99ngml
 1) and (4) a group receiving a combination
of dasatinib 50mgkg
 1 and docetaxel 5mgkg
 1 (n¼8, PSA –
6.045±1.098ngml
 1). There were no differences in enrolment
PSA levels (ANOVA, P¼0.5834). Dasatinib was administered via
gavage once a day for 5 days a week. Docetaxel was administered
via intraperitoneal injection every 2 weeks. Animals were killed
7 weeks after enrolment or if compromised. Blood samples were
drawn weekly for determination of serum PSA levels. Radiographs
(Faxitron Specimen Radiography System, Model MX-20; Faxitron
X-ray Corporation, Wheeling, IL, USA) and BMD levels were
assessed just before killing (PIXImus Lunar densitometer; GE
Healthcare, Waukesha, WI, USA). Calcium levels were determined
in sacrifice serum (Quantichrom Calcium Assay Kit; BioAssay
Systems, Hayward, CA, USA). For analyses, one animal from
the control group and one animal from the docetaxel alone group
were excluded because the tumour invaded into the surrounding
soft tissue based on palpation and high serum PSA level
(PSA4100ngml
 1) 6 weeks after enrolment.
Subcutaneous tumour models were also used for in vivo
analysis. Approximately 2 10
6 C4-2B were injected subcuta-
neously into SCID mice. Once tumour volumes reached approxi-
mately 250mm
3, animals were randomised to receive either
placebo or dasatinib (50mgkg
 1 gavage). Animals were killed
2h after administration of drug and the tumours harvested. Half
of each tumour was paraffin embedded and the other half flash
frozen for molecular analysis. Five animals were examined from
each group.
Immunohistochemistry
After killing, both tibiae and subcutaneous tumours were fixed
in 10% neutral buffed formalin for 24h. The tibiae were then
decalcified for 48h in 10% EDTA and then both tibiae and
subcutaneous tumours were processed for paraffin embedding.
Five-micron sections where used for H&E and IHC. IHC was
performed as we described previously (Kiefer et al, 2004) using the
rabbit polyclonal anti-phospho-SFK antibody (1:100; Cell Signal-
ing). Negative control slides were performed with rabbit polyclonal
IgG (1:100).
Statistical analyses
Statistical analyses were performed using unpaired student t-tests
and ANOVA (Prism Graphpad; Graphpad Software, San Diego,
CA, USA). Significant results were determined as a Pp0.05.
RESULTS
In vitro effects of dasatinib on C4-2B cells
Previous studies have shown that dasatinib inhibits proliferation of
LNCaP, PC-3 and DU-145 CaP cells in vitro (Lombardo et al, 2004;
Nam et al, 2005). The effects of dasatinib on C4-2B have not been
previously evaluated, and therefore, we first examined the effects
of dasatinib on these cells in vitro. Similar to other CaP cell lines,
dasatinib significantly decreased proliferation of C4-2B cells in a
dose-dependent fashion (ANOVA, Po0.001) with an IC50 value of
3536nM (Figure 1A). Concordant with the inhibition of prolifera-
tion, PSA levels in the media were also significantly decreased
(ANOVA, Po0.0001). We also calculated the ngml
 1 of PSA per
10
5 cells, and these data show that PSA production per 10
5 cells
was only minimally affected by dasatinib up to 3000nM (decreases
of 1–4%). However, with the highest concentration of dasatinib
tested, PSA per ngml
 1 per 10
5 cells was significantly lower than
Dasatinib inhibits growth of prostate cancer in bone
T Koreckij et al
264
British Journal of Cancer (2009) 101(2), 263–268 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sthat of the control cells (44.2±1.4%) but significant inhibition of
proliferation was also noted at this concentration. These data
suggest that dasatinib inhibits proliferation of C4-2B cells without
largely affecting PSA production at concentrations between 12 and
3000nM, although large decreases are seen with high concentra-
tions of dasatinib (9000nM).
We also show that dasatinib inhibited SFK activation in C4-2B
cells. The inhibition of phospho-SFK formation was detected
30min after treatment with 100nM dasatinib and was sustained up
to 24h (Figure 1D). However, this western blot does not allow for
determinations regarding the specific phosphorylation status of
individual members of SFK.
It has been previously reported that lyn has a prominent role
in the control of proliferation of PC-3 CaP cells in vitro whereas
src played a more significant role as a mediator of migration
(Park et al, 2008). Therefore in our subsequent experiments, we
investigated the effects of dasatinib on phosphorylation of lyn
and src, specifically, in C4-2B cells. We used a combination of
immunoprecipitations (IP) with specific anti-lyn and src anti-
bodies to pull out these proteins and a western blot with the anti-
phospho-SFK Tyr
416 antibody because there are no specific
antibodies for phospho-lyn or phospho-src. Our IP results show
that in C4-2B cells, dasatinib inhibited phosphorylation of src,
although phosphorylation of lyn was unaffected (Figure 1C). We
also show that treatment with dasatinib did not affect protein
levels of src and lyn (Figure 1C).
In vivo effects of dasatinib on tumour growth in bone and
bone remodelling
Administration of dasatinib significantly decreased serum PSA
levels in tumour-bearing animals when compared to tumour-
bearing control animals (Figure 2). Normalised values of serum
PSA levels at killing to the enrolment serum PSA levels in animals
treated with dasatinib were 2.3±0.4 vs 9.2±2.1 in the control
animals (P¼0.004). Sacrifice serum PSA levels in animals treated
with dasatinib in combination with docetaxel were 1.02±0.2,
which is significantly lower than PSA levels in dasatinib-alone-
treated animals (P¼0.010) and control animals (Po0.001).
Administration of docetaxel decreased sacrifice serum PSA levels
to 6.1±0.7 but these differences did not reach significance
(compared to control animals; B30% decrease, P¼0.22). To
further evaluate tumour burden, we also compared the weight
of treated and untreated tumoured tibiae excised after killing.
There were decreases in the weight of the treated tumoured tibiae
vs control tumoured tibiae (expressed as percentage of con-
trol docetaxel: 58.9±18.4%, dasatinib: 65.0±10.8% and dasati-
nibþdocetaxel: 41.5±3.6%). However, these results did not reach
significance due to a large variation of the values in the control
group. Representative radiographs taken before killing are shown
in Figure 2B.
We have previously published that despite the stimulation of
bone formation by the growth of C4-2 cells in the tibiae, tumoured
tibiae showed decreases in BMD and trabecular bone volume
(Pfitzenmaier et al, 2003; Morrissey et al, 2007). Knowing the
significant role src plays in the regulation of osteoclast activity,
we, therefore, examined alterations in BMD in tibiae of animals
treated with dasatinib. The growth of C4-2B cells in the tibiae of
untreated control animals resulted in B20% decrease in BMD vs
contralateral non-tumoured tibiae (Figure 3B). Our results show
that treatment with dasatinib resulted in 25±1.4% greater BMD
of tumoured tibiae over control tumoured tibiae (Po0.001;
Figure 3A). In this experiment, treatment with docetaxel did not
significantly affect BMD of tumoured tibiae vs control tumoured
tibiae (P¼0.096). We also compared loss of BMD between
tumoured and contralateral non-tumoured tibiae in the untreated
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Figure 1 Effects of dasatinib on cellular proliferation: (A) Dasatinib inhibited proliferation of C4-2B cells. The cells were treated with 0, 12, 33, 111, 333,
1000, 3000 or 9000nM dasatinib for 72h, ANOVA Po0.0001. Data are plotted as mean±s.e.m. (B) Dasatinib treatment resulted in decreases in total
levels of PSA in the culture media from the proliferation studies. (C) Immunoprecipitation (IP) for lyn and src. Treatment with dasatinib decreased
phosphorylation of src but not lyn at Tyr
416. Western blot analysis of whole cell lysates demonstrates that dasatinib did not affect total protein levels for lyn
or src. (D) Western blot analysis – 100nM dasatinib inhibited src family kinase (SFK) phosphorylation after 0.5, 1, 2, 4, 6 and 24h.
Dasatinib inhibits growth of prostate cancer in bone
T Koreckij et al
265
British Journal of Cancer (2009) 101(2), 263–268 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sgroup. Dasatinib alone and in combination with docetaxel
significantly inhibited this loss of BMD (Po0.001; Figure 3B).
Tumoured tibiae treated with dasatinib showed only an 8% loss in
BMD compared to contralateral non-tumoured tibiae. Again,
docetaxel alone did not affect the loss in BMD between
contralateral tibiae (22% loss in BMD). Offering further proof
of inhibition of osteolysis, on H&E stains, we show increased bone
formation in tumoured tibiae receiving treatment with dasatinib
alone and in combination (Figure 3D).
The inhibition of osteolysis by dasatinib was not limited to the
tumoured tibiae. When we compared the BMD of non-tumoured
tibiae of those animals treated with dasatinib alone and in
combination vs non-tumoured tibiae of the docetaxel-treated and
control animals, our results showed that dasatinib caused
increased BMD of the normal tibiae of treated animals
(10±1.9%, P¼0.0007). Examination of BMD of the entire animal
revealed an increase of 6±1.2% (P¼0.001) in the dasatinib and
combination therapy-treated animals over the docetaxel-treated
and control animals. The systemic inhibition of osteolysis by
dasatinib was further confirmed by the significant decreases in
calcium levels in sacrifice serum from those animals receiving
dasatinib and combination therapy vs control and docetaxel-
alone-treated animals (dasatinib alone and in combination
animals: 1.34±0.09mmoll
 1; docetaxel alone and control animals:
1.61±0.06mmoll
 1, P¼0.027).
Immunohistochemistry of C4-2B subcutaneous tumours
To demonstrate that dasatinib inhibits SFK phosphorylation in
vivo, we first stained intratibial tumours; however, the process of
decalcification negatively affects the stability of phosphorylated
proteins and we obtained negative results. Therefore, as an alter-
native, we have chosen to perform IHC on subcutaneous tumours
treated with the same dose of dasatinib. Our results show strong
immunoreactivity of phospho-SFK in the control C4-2B subcuta-
neous tumours, and minimal staining in the dasatinib-treated
tumours (Figure 2C). Appropriate negative controls exhibited no
immunoreactivity (data not shown).
DISCUSSION
Therapy for patients with metastatic CaP typically involves
androgen deprivation. Although this therapy is effective initially,
most patients will ultimately develop castration-resistant CaP. At
that point, the current standard of care is chemotherapy with
docetaxel, which offers an incremental survival advantage for these
patients. This underscores the need for additional therapies in
treating patients with metastatic CaP. A potential avenue for
improving outcomes for patients with metastatic CaP involves the
use of small molecule inhibitors of signalling pathways either alone
or in combination (McCarty, 2004). SFK inhibitors fall into this
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Figure 2 Effects of dasatinib and docetaxel in vivo:( A) Dasatinib alone and in combination with docetaxel significantly inhibited serum levels of PSA. PSA
levels were normalised to enrolment PSA. Doc¼docetaxel (5mgkg
 1) alone; Das¼dasatinib (50mgkg
 1) alone; Doc/Das¼Combination therapy. Data
are plotted as mean±s.e.m. (B) Representative radiographs of tibiae taken just before killing: (1) Normal non-tumoured tibiae; (2) C4-2B tumoured tibia –
control group; (3) C4-2B tumoured tibia of animal treated with docetaxel; (4) C4-2B tumoured tibia of animal treated with dasatinib alone; (5) C4-2B
tumoured tibia of animal treated with dasatinibþdocetaxel. Notice the mixed osteolytic/osteoblastic lesions associated with growth of C4-2B in untreated
and docetaxel-treated tibiae. (C) Effect of dasatinib of on inhibition of src phosphorylation of C4-2B subcutaneous tumours. Near complete inhibition of src
family kinase phosphorylation is demonstrated with dasatinib treatment. Animals treated 2h before killing. Negative control slides were negative (data not
shown).  10 magnification. (D) H&E of representative tibiae. Note the increasing amounts of bone formation with the administration of dasatinib (black
arrows). Doc¼docetaxel alone; Das¼dasatinib alone; Doc/Das¼Combination therapy.  10 magnification.
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scategory and there are several of these being evaluated in both the
preclinical and clinical setting. As src levels are increased in
advanced CaP and possibly even more so in castration-resistant
disease, we sought to investigate the efficacy of a src inhibitor,
dasatinib, in treating CaP growth in bone.
We have demonstrated that dasatinib inhibits proliferation of
C4-2B CaP cells in vitro. Most importantly, we showed that PSA
production is not affected in the absence of growth inhibition. This
point is critical to our in vivo studies as it allows for PSA levels to
be used as a surrogate marker for tumour growth in bone in
response to this therapy. Also of interest, despite recent literature
demonstrating the importance of the SFK member, lyn, in
regulating proliferation of PC-3 CaP cells (Park et al, 2008); we
show that lyn phosphorylation is unaffected in C4-2B cells on
treatment with dasatinib. Thus implying that lyn inactivation
is not involved in the inhibition of proliferation by dasatinib in
these cells.
Our in vivo studies have indicated that dasatinib decreased
tumour growth in the bone environment. First, we used serum PSA
levels to evaluate effects on tumour growth, and our data showed
that dasatinib caused decreases in serum PSA. This effect is
important, as PSA levels are the major surrogate marker of anti-
tumour response in tumours growing intratibially while under
treatment. Although it is generally accepted that in primary
disease PSA correlates with tumour volume, it is also noted from
preclinical and clinical data that in advanced castration-resistant
CaP, changes in serum PSA levels do not necessarily reflect
changes in tumour volume. We believe, however, that our in vitro
results allow us to extrapolate that the decreases in serum PSA
levels seen in mice bearing intratibial tumours are synonymous
with decreases in tumour volume. To further confirm dasatinib
inhibition of tumour growth by means other than serum PSA
levels, we examined the weight of the tibiae with tumour.
The decreases in weight of the tibiae observed in those groups
receiving either docetaxel, dasatinib or a combination compared
to the control group help to substantiate the claim that treatment
resulted in decreased tumour burden. This may be especially
accurate for dasatinib (alone or in combination)-treated tibiae
where decreases in tibiae weight were seen despite increases in
BMD, which implies that the weight loss is related to decreases
in tumour volume and not bone destruction. The increased
BMD of the groups receiving dasatinib alone or in combi-
nation may also be a result of decreased tumour growth and not
solely related to the effect that dasatinib has on regulating
osteoclast activity. Altogether, these data indicate that dasatinib
has a significant cytotoxic effect on CaP cells in the bone
environment.
An issue to mention is the lack of significant effects seen in the
docetaxel monotherapy group. Our previous work with docetaxel
had shown that the dose of 5mgkg
 1 to be an efficacious dose,
albeit those studies were performed on a different cell line. In this
study, the docetaxel when used alone did slow tumour growth by
B30%, but these results did not reach significance. However, when
docetaxel was used in combination with dasatinib, the dose
resulted in significant decreases in PSA levels beyond those seen
with the administration of dasatinib alone. We have previously
seen this increased efficacy with the use of other pharmaceuticals
in combination with docetaxel over either agent alone (Brubaker
et al, 2006; Morgan et al, 2008). In addition, src inhibition has been
reported to increase sensitivity of other advanced cancers to
several already used chemotherapies and specifically to docetaxel
resistance (Yezhelyev et al, 2004; Han et al, 2006). This
phenomenon may have important implications for patient care
as of the efficacy of docetaxel therapy may be enhanced with the
addition of dasatinib. Nonetheless, final conclusions regarding
effects of dasatinib in this regard will require additional clinical
investigations.
Src is an important player in forming the cell–cell junctions
necessary for bone resorption to take place, and it has been
clearly shown that inhibition of src activity decreases bone
osteolysis. However, our results are the first to show that
dasatinib treatment results in increases in BMD of normal bone
as well as increases in BMD of bone harbouring an osteolytic
tumour. The ability of dasatinib to increase BMD may prove to be
beneficial to patients with CaP where skeletal related events (SRE;
ie, pathologic fractures, spinal cord compression) and bone pain
are a significant source of morbidity. Additionally, even patients
without bone metastases suffer an increased risk of osteoporotic
fractures from the effects of androgen deprivation. Agents that can
cause increases in BMD have been investigated in metastatic
prostate cancer. The bisphosphonate, zoledronic acid, has been
shown to increase time to first SRE as well as reduced the number
of SREs in patients with castration-resistant metastatic prostate
cancer (Saad et al, 2004). Inhibition of RANKL has also been
shown to increase BMD in experimental prostate cancer bone
metastasis models (Ignatoski et al, 2008) and inhibitors
(AMG162, denosumab) are currently in clinical trials. These
agents have been shown to affect tumour growth mainly via
indirect mechanisms by inhibiting bone lysis. In contrast,
decreasing activity of src has been shown not only to inhibit
osteolysis but also directly inhibit tumour growth. Therefore,
the use of compounds such as dasatinib has the potential to
provide pronounced benefit for metastatic prostate cancer
patients.
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Figure 3 Effects of dasatinib and docetaxel on BMD: (A) Comparison
BMD of disease tibiae. Analysis via Student’s t-test. (B) Comparison of
BMD between diseased and non-diseased tibiae. Doc¼docetaxel
(5mgkg
 1) monotherapy; Das¼dasatinib (50mgkg
 1) monotherapy;
Doc/Das¼Combination therapy; R¼right (tumoured tibiae); L¼left
(non-tumoured tibiae). Numbers above the columns represent the
decrease in BMD between normal tibiae and contralateral tumoured
tibiae.
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sIn summary, our results indicate that dasatinib inhibits the growth
of CaP in bone, and these inhibitory effects are increased in
combination with docetaxel. Additionally, our study demonstrates
decrease in osteolysis in dasatinib-treated animals, both in the tumour
as well as normal bone. Our results suggest that dasatinib alone or in
combination should be further investigated in a clinical setting for
patients with metastatic CaP, and these studies are currently ongoing.
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